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For more than a century and a half, the description of a liver as “cirrhotic” was sufficient to
connote both a pathological and clinical status, and to assign the prognosis of a patient with
liver disease. However, as our interventions to treat advanced liver disease have progressed
(e.g., antiviral therapies), the inadequacy of a simple one-stage description for advanced
fibrotic liver disease has become increasingly evident. Until recently, refining the diagnosis of
cirrhosis into more than one stage hardly seemed necessary when there were no interventions
available to arrest its progression. Now, however, understanding the range of potential
outcomes based on the severity of cirrhosis is essential in order to predict outcomes and
individualize therapy. This position paper, rather than providing clinical guidelines, attempts
to catalyze a reformulation of the concept of cirrhosis from a static to a dynamic one, creating
a template for further refinement of this concept in the future.
We already make the clinical distinction between compensated and decompensated cirrhosis,
and are incrementally linking these clinical entities to quantitative variables such as portal
pressure measurements and emerging noninvasive diagnostics. Moreover, mounting evidence
suggests that cirrhosis encompasses a pathological spectrum which is neither static nor
relentlessly progressive, but rather dynamic and bidirectional, at least in some patients. Thus,
there is a pressing need to redefine cirrhosis in a manner that better recognizes its underlying
relationship to portal hypertension and related circulatory changes, and more faithfully reflects
its progression, reversibility and prognosis, ultimately linking these parameters to clinically
relevant outcomes and therapeutic strategies. The Child-Pugh and Model for End-Stage Liver
Disease (MELD) scores are currently deployed to define prognosis by modeling hepatic
dysfunction, but do not provide direct evidence of the stage or dynamic state of cirrhosis. The
need for more refined cirrhosis staging is especially germane given the increasing use of
effective antiviral treatments in patients with hepatitis B virus (HBV) and hepatitis C virus
(HCV) cirrhosis and the emergence of effective antifibrotic agents, wherein we must define
favorable or unfavorable endpoints that correlate with a discrete clinical outcome in patients
with cirrhosis.
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The normal liver has only a small amount of fibrous tissue in relation to its size. As a result of
continued liver injury, however, there is progressive accumulation of extracellular matrix, or
scar. Although different chronic liver diseases are characterized by distinct patterns of fibrosis
deposition,1 the development of cirrhosis represents a common outcome leading to similar
clinical consequences that impose an increasing burden in clinical practice.
Anatomical-Pathological Context
Cirrhosis is defined histologically as a diffuse process in which the normal anatomical lobules
are replaced by architecturally abnormal nodules separated by fibrous tissue.2 Progressive
histological stages have been defined in the process leading to the development of cirrhosis.
Among the more common staging systems, the METAVIR scale is distinguished by four stages,
with stage F0 representing lack of fibrosis; stage F1, portal fibrosis; stage F2, periportal
fibrosis; stage F3, bridging fibrosis; and, finally, stage F4 representing cirrhosis.3 Similarly,
the Ishak4 and Scheuer scoring systems5,6 attempt to semi-quantitatively define progressive
fibrosis based on the pattern and relative amounts of scar within a liver biopsy specimen. In
this context, once fibrosis reaches the final stages, the diagnosis of cirrhosis is established and
the process is considered “end-stage” from a pathological perspective.
Clinical Context
Cirrhosis has also been increasingly defined by clinical outcomes. In this context, cirrhosis is
distinguished between compensated and decompensated stages, with different features,
prognoses and predictors of death.7 Within the compensated stage, two subpopulations have
been identified based on the absence or presence of varices, each of which confers a distinct
prognosis. Decompensated cirrhosis is defined by the development of clinically evident
complications of portal hypertension (ascites, variceal hemorrhage, hepatic encephalopathy)
or liver insufficiency (jaundice). The decompensated stage can be subclassified further into a
more severe stage defined by the development of recurrent variceal hemorrhage, refractory
ascites, hyponatremia and/or hepatorenal syndrome.
Hemodynamic Context
Portal hypertension is the earliest and most important consequence of cirrhosis and underlies
most of the clinical complications of the disease. Portal hypertension results from an increased
intrahepatic resistance combined with increased portal (and hepatic arterial) blood flow. The
increased intrahepatic resistance is the result of architectural distortion (fibrous tissue,
regenerative nodules), endothelial dysfunction leading to intrahepatic vasoconstriction, and
intrahepatic vascular shunts between afferent and efferent vessels of the liver.8 In addition,
cirrhosis is accompanied by extrahepatic hemodynamic abnormalities: vascular resistance in
the splanchnic and systemic circulations in cirrhosis is decreased, leading to an increase in
splanchnic blood flow that contributes to the maintenance of the portal hypertensive state.9
This vasodilatation is due to an increased production of nitric oxide.8 Splanchnic and systemic
vasodilatation are not only responsible for increasing portal inflow and variceal enlargement,
but they also initiate the hyperdynamic circulatory state of cirrhosis that leads to other major
complications such as ascites. Moreover, vasodilation and increased portal flow are more
extreme in patients with further decompensation of cirrhosis (i.e., refractory ascites,
hyponatremia and hepatorenal syndrome).
The hepatic venous pressure gradient (HVPG), an indirect measure of portal pressure, is the
best predictor of the development of varices,10 and is also a harbinger of decompensation (e.g.,
ascites, variceal hemorrhage and encephalopathy).11 Normal HVPG is 3–5 mmHg,
whereas>10 mmHg is a threshold that identifies patients at risk of developing varices, and/or
clinical decompensation. Thus, HVPG > 10 mmHg defines the presence of “clinically
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significant portal hypertension”. Notably, recurrent variceal hemorrhage and ascites do not
occur when the HVPG is reduced to levels below 12 mmHg, and therefore this threshold is
closely related to the presence of decompensating events.12–14
In decompensated cirrhosis, an HVPG>20 mmHg is an important predictor of a poor outcome
in the setting of acute variceal hemorrhage.15 In addition to portal pressure, however, the
systemic hemodynamic alterations of cirrhosis play an important role in the development of
further decompensating events such as refractory ascites, hyponatremia and the hepatorenal
syndrome. Remarkably, elevated HVPG also correlates with the risk of hepatocellular
carcinoma.16
Histological, Clinical, and Hemodynamic Correlations
As noted above, the histologic features of cirrhosis have not been traditionally linked to clinical
outcomes. However, there is recent evidence indicating that both HVPG and semiquantitative
features of histology do indeed predict hemodynamic and clinical features of chronic liver
disease and cirrhosis. For example, progressive increases in HVPG correlate with increasing
severity of liver disease (normal, chronic hepatitis, precirrhosis, and cirrhosis) both in
alcoholic17 and in nonalcoholic liver disease.18 Patients with fibrosis stages 3 or 4 almost
uniformly have an HVPG of ≥ 6 mmHg. In a recent study of posttrans-plant recurrent hepatitis
C, fibrosis stage in liver biopsies correlated with concurrent HVPG measurements when
performed 1 year after transplantation.19 Notably, a significant proportion of patients who did
not have a histological diagnosis of cirrhosis had an HVPG>6 mmHg (i.e., they had portal
hypertension) and, upon follow-up, HVPG was more predictive of clinical decompensation
than histological fibrosis staging.
Simple histologic features may also have important prognostic implications in cirrhotic liver
biopsies. For example, the thickness of fibrous septa correlates with HVPG and is an
independent predictor of both clinically significant portal hypertension (i.e., HVPG>10
mmHg)20 and clinical decompensation.21 Moreover, digital image analysis of septal thickness,
but not total fibrosis area, predicts cirrhosis decompensation.22
Biological Context
Studies performed in the past two decades have identified several attractive targets for
antifibrotic treatment. These include the major cellular sources of scar, most notably activated
hepatic stellate cells and portal myofibroblasts, as well as key cytokines such as platelet-derived
growth factor and transforming growth factor beta.23 The roles of bone marrow–derived cells
and those arising from epithelial-mesenchymal transition are still under evaluation, but it is
unlikely that these sources of fibrogenic cells provide a major contribution to hepatic
extracellular matrix in chronic human liver disease. Cellular sources of proteases that degrade
scar and the pathways that regulate them are better understood. Moreover, a more nuanced
understanding of distinctive pathogenic features of fibrosis at different stages and from
different etiologies means that fibrosis may be customized according to its duration and
underlying cause.
Cirrhosis in experimental models and human disease may be reversible.24 Following
withdrawal of an injurious stimulus, a dense micronodular cirrhosis can undergo remodeling
to a more attenuated, macronodular pattern. However, some septa will persist, likely
representing those laid down early in the injury and are therefore the most “mature” (i.e., cross-
linked).
Moreover, in experimental models, such mature scars may be the site of neoangiogenesis. Such
angiogenesis is already present in chronic inflammatory liver diseases25 concurrent with the
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fibrogenic process and may also play a role in the pathogenesis of portal hypertension.26 The
effectiveness of therapeutic angiogenic inhibitors in not only improving fibrosis, but also in
reducing portal pressure, is suggested by data from animal models but has not been established
in humans.27 Although there are no data linking septal remodeling to portal pressure changes,
recent work correlating increased portal hypertension with smaller nodule size and septal
thickening suggests that reversal of these events might lower portal pressure.20
These rodent models and human studies throw into relief the inadequacy of a simple one stage
classification, because although the micronodular and remodeled attenuated macronodular
cirrhosis are very different, they are both defined by the same original pathologic description:
“cirrhosis”. These same experimental models have also facilitated the comparative study of
reversible and irreversible septa. Specific septal changes that are associated with irreversibility
include: matrix modification with cross-linking, elastin-rich scars, and septal
neovascularization. Additionally, the loss of cells that drive matrix turnover from the septa
combined with vascular extinction may both limit reversibility. Lastly, of course, the
persistence and intensity of the initiating injury will affect the progression of cirrhosis via
recurrent cycles of inflammation and repair, regardless of the capacity of the liver to restore a
more normal architecture.
Should antifibrotic therapies emerge, the challenges of therapeutically resorbing fibrosis in a
cirrhotic liver will be quite different from those of a noncirrhotic liver for several reasons. First,
whereas evidence clearly indicates reversibility of fibrosis in precirrhotic disease, the
determinants of fibrosis regression in cirrhosis are not sufficiently clear, and the point at which
cirrhosis is truly irreversible is not established, either in morphologic or functional terms.
Second, there is a heightened sense of urgency in attempting to regress fibrosis in cirrhosis,
because continued progression might lead to imminent decompensation, whereas noncirrhotic
disease could be decades away from clinical consequences. Thus, the speed of regression in
cirrhosis may need to be greater, yet, the cirrhotic liver with its thicker, more cross-linked septa
and distorted vasculature may be less amenable to treatment. On the other hand, since fibrosis
is part of a chronic wound healing reaction to encapsulate tissue damage, preventing the
formation of scar tissue without removing the cause of damage might be detrimental by
amplifying the injury. Ideally, therefore, administration of an antifibrotic agent would be most
useful when coupled with an effective treatment for the underlying liver disease (e.g., antiviral
drugs in patients with HBV or HCV). In contrast, in cirrhotic liver, where the ultimate goal is
the reduction of portal pressure, the use of antifibrotic agents coupled with effective treatments
to reduce portal pressure and its hemodynamic consequences might be more rational.
What Is Cirrhosis?
Currently, the diagnosis of cirrhosis in diffuse disease (viral hepatitis, alcohol) relies primarily
on histopathological evidence of late-stage fibrosis (e.g., stage 4 fibrosis using the METAVIR
system, or stages 5 or 6 in the Ishak scoring system). In this context, and particularly in chronic
hepatitis C, sampling errors may lead to underdiagnosis28 or overdiagnosis of cirrhosis.19
Regardless, when using these and related staging systems, “cirrhosis” is a static diagnosis
reflecting the end stage of the wound healing process, without adequately signifying the
complexity of its pathogenesis, or its functional, hemodynamic and prognostic correlates.
Because these collective changes are fundamental to provoking the transition from
compensated to decompensated cirrhosis, we need a far more refined pathophysiological
classification of compensated cirrhosis based on morphological, functional, and clinical data
(Fig. 1).
At the least, a revised staging of cirrhosis should start with its main classification of
compensated and decompensated cirrhosis. Compensated cirrhosis in turn would comprise two
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substages: without varices (stage 1) or with varices (stage 2). However, staging of compensated
cirrhosis could be further refined as (1) no portal hypertension (HVPG <6 mmHg); (2) portal
hypertension that is not clinically significant (HVPG between 6 and 10 mmHg); and (3)
clinically significant portal hypertension (HVPG>10 mmHg or presence of collaterals).
Substaging of decompensated cirrhosis is not as well-defined but would likely be classified
according to both the degree of portal hypertension and the degree of liver/circulatory
dysfunction (with recurrent variceal hemorrhage, refractory ascites, and hepatorenal syndrome
representing more severe stages) (Fig. 1). It remains possible that additional technologies apart
from HVPG will emerge that can further discriminate the pathological and functional state of
the liver. Such information could be vital to optimize the timing and nature of antifibrotic
therapies, or the need for liver transplantation. Thus far, liver stiffness measurement (LSM)
obtained by transient elastography is the most promising noninvasive approach for monitoring
fibrosis progression associated with worsening portal hypertension. LSM has an excellent
correlation with HVPG values below a threshold of 10–12 mmHg.29,30 Although these
findings need to be further substantiated in larger independent studies, they suggest that LSM
may be useful in the detection of clinically significant portal hypertension and, thereby, in
further subclassifying compensated cirrhosis. On the other hand, LSM may not be accurate in
decompensated cirrhosis where, in addition to intrahepatic vascular resistance, there are
complex hemodynamic changes.31 Nonetheless, it will be important to evaluate, in
longitudinal studies, whether single LSM values or dynamic changes over time are predictive
of initial or further decompensation, or the response to pharmacological therapy.32,33
We encourage the practicing community, pathologists, and investigators to move beyond the
simple characterization of cirrhosis as a single stage and instead begin thinking of cirrhosis as
a series of critical steps that, if left unchecked, culminate in hepatic decompensation. A new
framework for classifying cirrhosis will require integration of both current and emerging
knowledge about liver structure and function. From one stage, there should emerge many.
Abbreviations
HVPG hepatic venous pressure gradient
LSM liver stiffness measurement
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Fig. 1.
Classification of chronic liver disease based on histological, clinical, hemodynamic, and
biological parameters. In the noncirrhotic stage (METAVIR F1–F3), there is no clinical
evidence of cirrhosis, the HVPG is below 6 mmHg, and at this stage there is fibrogenesis and
neovascularization. The cirrhotic stage (METAVIR F4) is broadly classified into two stages:
compensated and decompensated, with clinical decompensation being defined by the
development of ascites, variceal hemorrhage (VH), encephalopathy, and jaundice. Within the
compensated stage, patients can be subclassified into those without varices (stage 1) and those
with varices (stage 2). Those without varices can be further subclassified into those with an
hepatic venous pressure gradient (HVPG) < or > 10 mmHg, which is the threshold pressure
that predicts development of varices and decompensation. HVPG > 10 mmHg (clinically
significant portal hypertension) correlates with thick scar and small nodules. In the
decompensated stage, the scar is resistant to degradation. Complex circulatory (splanchnic and
systemic) abnormalities that occur at this decompensated stage contribute to further
decompensation, i.e., recurrent variceal hemorrhage, refractory ascites, and hepatorenal
syndrome, and although HVPG retains prognostic value, other parameters that take into
account liver insufficiency and a deranged circulatory state, such as the MELD score, are more
predictive of death (not depicted in figure). Figure is modified from Friedman.23
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